TABLE 3.

Change in pre-bronchodilator FEV₁ from baseline to week 52 in patients with and without PAO by baseline BEC and F_ENO level

Biomarker level at baseline	Patients with PAO					Patients without PAO
	LS mean±se change from baseline L				LS mean difference (95% CI) L	LS mean±se change from baseline L				LS mean difference (95% CI) L
	Tezepelumab 210 mg Q4W	n	Placebo	n		Tezepelumab 210 mg Q4W	n	Placebo	n
BEC cells·µL−1
<150	0.03±0.05	79	−0.01±0.04	91	0.04 (−0.08–0.17)	0.10±0.05	87	0.17±0.05	80	−0.07 (−0.19–0.06)
≥150	0.30±0.02	306	0.10±0.02	302	0.20 (0.14–0.27)	0.24±0.03	187	0.10±0.03	194	0.15 (0.07–0.23)
<300	0.10±0.03	198	0.02±0.03	209	0.08 (0.00–0.16)	0.13±0.03	177	0.11±0.03	172	0.03 (−0.06–0.11)
≥300	0.40±0.03	187	0.13±0.03	184	0.27 (0.18–0.35)	0.32±0.04	97	0.13±0.04	102	0.19 (0.08–0.30)
FENO level ppb
<25	0.12±0.03	166	0.04±0.03	157	0.08 (−0.01–0.17)	0.15±0.04	123	0.12±0.04	136	0.03 (−0.07–0.13)
≥25	0.33±0.03	217	0.09±0.03	233	0.24 (0.17–0.32)	0.25±0.04	145	0.12±0.04	136	0.14 (0.04–0.23)
<50	0.17±0.03	286	0.04±0.03	275	0.13 (0.07–0.20)	0.20±0.03	193	0.11±0.03	198	0.09 (0.01–0.17)
≥50	0.44±0.04	97	0.14±0.04	115	0.30 (0.19–0.41)	0.23±0.05	75	0.15±0.05	74	0.08 (−0.05–0.21)

FEV₁: forced expiratory volume in 1 s; PAO: persistent airflow obstruction; BEC: blood eosinophil count; F_ENO: fractional exhaled nitric oxide; LS: least-squares; Q4W: every 4 weeks.